Treatment of thrombotic complications in patients with MPN

Thrombotic events represent the most significant complications in patients with MPN, with a primary treatment goal of reducing their frequency and reccurrence.¹ In current clinical practice, patients with either a history of thrombosis or aged ≥60 years are classed as high thrombotic risk and managed with cytoreductive treatment.¹ More precise thrombotic risk evaluation may be feasible using other factors, such as the presence of a high (>1%) JAK2V617F allele burden.¹ 

A recent review by Guy et al., published in Blood, incorporates case-based discussions and explores optimal antithrombotic treatment types and therapy duration for thrombotic complications in patients with MPN, with a focus on oral anticoagulants and SVT management.¹